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ABSTRACT  
Background: Current guidelines recommend cardiac resynchronisation therapy (CRT) in mild 
HF patients with QRS prolongation and ejection fraction (EF) < 30%.  To assess the effect of 
CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses 
Remodeling in Systolic left vEntricular dysfunction( REVERSE) study were evaluated in which 
patients with LVEF > 30% were included.  
Methods and Results: The results of patients with baseline EF > 30% (n=177) to those with EF 
< 30% (n=431), as determined by a blinded core laboratory were compared.  In the LVEF > 30% 
subgroup there was a trend for improvement in the clinical composite response with CRT ON vs 
CRT OFF (p=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 
ml/m2 vs 2.1 ± 17.6 ml/m2, p=0.01) and LV mass (-20.6±50.5 g vs 5.0±42.4 g; p=0.04) after 12 
months.  The time to death or first HF hospitalization was significantly prolonged with CRT (p 
=0.012, hazard ratio=0.26).  
In the LVEF < 30% subgroup, significant improvements in clinical composite response (p=0.02), 
reverse remodeling parameters and time to death or first HF hospitalization (p =0.047, hazard 
ratio=0.58) were observed. After adjusting for important covariates, the CRT ON assignment 
remained independently associated with improved time to death or first HF hospitalization 
(p=0.035, hazard ratio=0.54) whereas there was no significant interaction with LVEF.   
Conclusion: Among subjects with mild HF, QRS prolongation and LVEF > 30%, CRT 
produced reverse remodeling and similar clinical benefit compared to subjects with more severe 
left ventricular systolic dysfunction.  
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Clinical Trial Registration: Clinicaltrials.gov identifier NCT00271154 
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Abbreviations: 
CCS= clinical composite score 
CRT= Cardiac resynchronization therapy  
ECG= electrocardiogram  
EF= ejection fraction 
HF= heart failure  
ICD= implantable cardioverter defibrillator  
KCCQ= Kansas City Cardiomyopathy Questionnaire 
LV= left ventricular  
LBBB= left bundle branch block 
LVESVi= left ventricular end-systolic volume index  
LVEDVi= left ventricular end diastolic volume index 
MLHFQ= Minnesota Living with Heart Failure Questionnaire 
NYHA= New York Heart Association 
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INTRODUCTION 
Cardiac Resynchronization Therapy (CRT) is well established for patients with severe left 
ventricular systolic dysfunction and ventricular conduction delay in advanced heart failure (HF) 
1-7.  More recently, the benefit of CRT was expanded to patients with mild HF, with improved 
functional status and reductions in hospitalization and mortality observed8-12.   The most 
consistent response was noted in subgroups with left bundle branch block (LBBB) and more 
prolonged baseline QRS duration13,14. However, the effect of left ventricular ejection fraction 
(LVEF) on CRT outcomes is less clear.  Based on these results, current guidelines recommend 
CRT as a Class I indication for subjects with mild heart failure, LBBB and LVEF < 3515,16 or 
30%17 with LVEF criteria based on the inclusion criteria in the studies15-17.  
Of the three multicenter, randomized trials of CRT in mild HF, only REVERSE included 
subjects with EF > 30%.  To determine whether CRT is effective in less severe left ventricular 
systolic dysfunction, the impact of EF on outcomes in REVERSE was studied.  Specifically, we 
hypothesized that the benefit from CRT would be similar in patients with moderate LV 
dysfunction (LVEF > 30%) as in those with severe LV dysfunction (LVEF < 30%). 
 
METHODS 
Study design and data collection: 
REVERSE was a prospective, randomized, double-blind, parallel-controlled study designed to 
determine whether CRT limited the progression of heart failure compared to optimal medical 
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therapy alone.  The study included ACC/AHA stage C, NYHA Class I or II heart failure patients 
with QRS ≥ 120ms, and LVEF ≤ 40% on optimal medical therapy.  Patients were implanted with 
a CRT device with (CRT-D) or without (CRT-P) defibrillator and randomized 2:1 to CRT ON 
versus CRT OFF.  Devices were then programmed as randomized through 12 months in North 
America and through 24 months in Europe. The rationale of the REVERSE study has been 
published previously18.  For the present analysis, patients were grouped by LVEF > 30% or < 
30%, by core lab evaluation. 
 
Outcomes: 
The primary endpoint of the REVERSE main study was the percentage of patients at 12 months 
with a worsened HF clinical composite score19 (CCS), which scores patients as improved, 
unchanged, or worsened. The prospectively powered secondary endpoint was LV end-systolic 
volume index (LVESVi). Other secondary endpoints were hospitalization for worsening HF and 
mortality and additional measures of reverse remodeling. Quality of life was measured by the 
Minnesota Living with Heart Failure Questionnaire (MLHFQ)20 and the Kansas City 
Cardiomyopathy questionnaire (KCCQ)21.  During the blinded period patients were evaluated 
every 6 months, by blinded staff collecting NYHA class, 6-minute hall walk, quality of life, 
echocardiographic data, HF-related hospitalizations and mortality data.  Heart failure 
hospitalizations were adjudicated for heart failure relatedness by the endpoint adjudication 
committee blinded to CRT assignment. This committee also adjudicated causes of death. 
Likewise, echocardiograms were assessed by two core labs blinded to CRT assignment, one in 
the US and one in Europe18.  
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Statistical methods:  
Statistical analyses followed the intent-to-treat principle.  All p-values reported are two-sided 
and do not adjust for multiple comparisons.  The primary endpoint was tested with a Fisher’s 
exact test that compared the full distribution of clinical composite scores at 12 months by 
randomization group.  The same testing procedure was used to assess NYHA class at 12 months.  
Kaplan-Meier curves were estimated for the combined endpoint of time to death or first HF 
hospitalization.  Time 0 was the date of randomization.   Since the length of the randomization 
period in the study differed by geography (12 months in North America and 24 months in 
Europe), patients without an observed event were censored at the end of their randomization 
period. Kaplan-Meier curves are truncated when fewer than 20 patients are at risk for a time 
point.  A log-rank test compared survival curves between randomization groups. To assess CRT 
effects on time to death or HF hospitalization modified by LVEF subgroup, a Cox model was fit 
with main effects for CRT and LVEF subgroup and an interaction effect between them.  The Cox 
model was then adjusted for other potentially confounding variables such as of age, intrinsic 
QRS duration, LVESVi, ischemic heart disease, and blood pressure at baseline.  There were 43 
patients with missing values for confounding factors that were discarded from the multivariable 
analysis. Within LVEF subgroup, changes between baseline and 12 months in LVEDVi, 
LVESVi, LVEF, LVEDD, LV mass,  MLWHF, KCCQ and the 6-minute hall walk were 
compared between randomization groups with a two-sample t-test assuming unequal variances.  
Finally,  regression towards the mean22 is a real concern in subgroup analysis where patients are 
divided into high and low groups.  To adjust for this effect, an ANCOVA model was fit for each 
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echo parameter where the outcome was the difference over time, the independent variable was 
CRT and the confounding variable was the baseline value of the echo parameter.  Statistical 
analyses were conducted in R (http://www.r-project.org) and SAS 9.2 (SAS Institute, Cary, 
North Carolina). 
 
RESULTS 
Patient Characteristics:  
The baseline characteristics of the entire cohort and the main results were reported 
previously9,10,22. LVEF was available in 608 of the 610 randomized patients, in 565 subjects by 
core lab measurement and in 43 by implanting center measurement. Of this cohort 431 patients 
(76.3%) had LVEF ≤ 30% and the remaining 177 patients (23.7%) had LVEF > 30%, including 
12.2% (n=74) with LVEF > 35%, reflecting the LVEF inclusion criterion of REVERSE.  The 
mean center LVEF (26.7±7.0) did not differ from core lab LVEF (27.0±6.6). The distribution of 
LVEF measurements at baseline is shown in Figure 1.  Consistent with clinical practice, the 
centers tended to report LVEF values in multiple of 5 (61.2%) or 10 (33.4%). Baseline 
characteristics grouped by LVEF are shown in Tables 1-2. Patients with LVEF > 30% were 
significantly older, more often had ischemic etiology, worse renal function and higher systolic 
blood pressure.  Nonetheless, they were more often in NYHA I, and had smaller LV dimensions 
and volumes and lower LV mass than those with LVEF < 30%. Moreover, quality of life both by 
the MLHFQ score and KCCQ and six minute walk distance tended to be better in the LVEF > 
30% group. Although QRS duration was significantly shorter in the LVEF > 30% group than in 
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the LVEF < 30% group (147±20.4 ms vs 155.7 ± 22.2 ms; p<0.0001), the presence of LBBB was 
comparable between subgroups (58% vs 62%, respectively, p= 0.31).  Both subgroups were well 
treated medically with most patients receiving both beta blockers and ACE inhibitors or 
angiotensin receptor blocker agents at baseline.  
 
Echocardiographic Measurements: 
The echocardiographic results are summarized in Figure 2 and in Table 3.  Overall the 
magnitude of improvement was smaller in the LVEF > 30% group than in the LVEF < 30% 
group.  A significant decrease of LVESVi after 12 months of CRT was observed in both LVEF 
subgroups compared to CRT OFF. A trend toward significant reduction in LVEDVi by CRT ON 
was observed in the LVEF > 30% group (-11.2 ± 27.0 ml/m2 vs -4.3 ± 22.9 ml/m2 in CRT OFF; 
p=0.12). A statistically significant decrease of LVEDVi and a significant increase in LVEF was 
only observed in the LVEF < 30% group.  Adjusting for the potential effect of regression to the 
mean did not affect the interpretation of the reverse remodeling results (Table 4). 
 
 Clinical Measurements: 
The clinical results at 12 months are shown in Table 3 and Figure 3. In the LVEF > 30% group 
the distribution of the CCS was better in CRT ON compared to OFF (p=0.06) but did not reach 
statistical significance. A statistically significant improvement was observed in the LVEF ≤ 30% 
group and in the full study group. In the overall group there was a significant improvement in 
NYHA class with CRT-ON (p=0.04). Although the numerical trends in the EF subgroups were 
in the same direction it did not reach statistical significance in either group.  
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Effect of CRT on time to first HF hospitalization or death in EF<=30 versus >30: 
Time to first HF hospitalization or death was tracked through 12 months (North America) or 24 
months (Europe) and is shown in Figure 4.  Overall the composite morbidity and mortality rate 
was nearly twice as high in the LVEF < 30% group; Death occurred in 3.7% of patients and 
11.8% experienced the composite endpoint of HF hospitalization or death during the 
randomization period. Comparatively, in the LVEF > 30% group, 1.7% of patients died and 
6.8% of patients experienced a HF hospitalization or death during the randomization period. 
There were significant prolonged time to first hospitalization for HF or death for CRT ON vs 
CRT OFF in both the LVEF ≤ 30% (p= 0.047, hazard ratio=0.58) and > 30% group (p=0.012, 
hazard ratio=0.26) with curves for CRT ON and OFF separating early within the first months 
(Figure 4).   
In the LVEF < 30% group there were 16 deaths: 6 /141 patients in CRT OFF due to progressive 
HF, arrhythmia, stroke, electromechanical dissociation, renal cancer and by cause unknown and 
10 /290 patients in CRT ON due to progressive HF (n=3), arrhythmia, bradyarrhythmia, 
pulmonary fibrosis, stroke, prostate cancer, and by cause unknown (n=2). In the LVEF > 30% 
group there were 3 deaths: 1/50 patients in CRT OFF (gastrointestinal bleeding) and 2/127 
patients in CRT ON (gastrointestinal bleeding and pulmonary fibrosis).  The effect of the 
interaction between CRT and LVEF subgroup on time to death or HF hospitalization was also 
assessed.  
As there were some baseline differences between the two LVEF subgroups, a multivariable 
analysis was performed to adjust for potential confounding factors (Table 5). After adjusting for 
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important covariates, the main effect for CRT assignment remained independently associated 
(p=0.035, hazard ratio=0.54) with improved outcomes among patients assigned to CRT ON.   
There was no statistically significant interaction between CRT and LVEF indicating that there 
was no evidence that the benefit of CRT varied with LVEF.  Baseline LVESVi (p=0.0002) and 
QRS duration (p=0.003) were also independently associated with hospitalization for HF or death 
with better outcome in subjects with smaller left ventricular size and longer QRS duration.  The 
etiology of heart disease (i.e. ischemic vs nonischemic) was not associated with outcome in this 
analysis.  
 
DISCUSSION 
The primary results of the present analysis show  that the beneficial effect of CRT-ON on 
ventricular function and on time to death or first hospitalization occurs across the full spectrum 
of LVEF studied in REVERSE, with no sign that it is weaker in patients with LVEF>30 than 
those with LVEF<=30. These findings are strengthened by the randomized design of the study, 
with blinded comparison against CRT-OFF, and the rigorous exclusion of regression to the mean 
as a contributing factor.  
Sub-studies of CRT results by different ejection fractions  
In previous sub-studies of randomized controlled studies, no apparent difference in CRT benefit 
was observed in patients with LVEF > 20% or < 20% in moderate to severe4,5  and mild11,12  
heart failure. Similar observations were made in a retrospective analysis of the PROSPECT study 
evaluating less severe LV dysfunction and an analysis of single center data24,25. PROSPECT26 
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was an open-label study which included patients with NYHA class III–IV, QRS > 130 ms and 
LVEF < 35%. CRT induced similar benefit among patients with LVEF < 35% or LVEF > 35% 
with regard to reverse remodeling and the percentage improved by the CCS. Importantly, a 
recently published post hoc analysis of MADIT-CRT27 of NYHA I-II patients also indicated a 
benefit of CRT in the subjects with LVEF > 30% in the study. As in our study and in 
PROSPECT26, core lab evaluation resulted in some subects with higher LVEF than allowed by 
the study inclusion criteria.   In agreement with our findings, the clinical benefit for time to HF 
hospitalizations or death was greater for the patients with LVEF > 30% compared to the other 
LVEF groups27. However, in contrast to our findings, the extent of reverse remodeling defined as 
decrease of LVESVi was higher for the LVEF > 30% patients27 than for the other groups in spite 
of smaller baseline LV. The reason for this discrepancy is not clear, although subjects with less 
severe LV dysfunction were included in REVERSE.  
Results in the present study with regard to LVEF 
To our knowledge, only REVERSE included patients with LVEF < 40%.  In fact 12.2% (n=74) 
of our patients had LVEF > 35%, i.e. with LVEFs beyond the current guideline 
recommendations in the US15,16. In contrast, a smaller fraction of patients in the MADIT CRT 
sub-study had LVEF > 35%. Our results show some signs of significant reverse remodeling 
benefits by CRT at 12 months regardless of whether baseline LVEF was below or above 30%. In 
this study the patients with higher LVEF were more often older, had more ischemic heart disease 
and worse renal function implying negative prognostic impact. However, they were more often 
in NYHA I functional class and had smaller baseline LV volumes than patients with LVEF < 
30%.  
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Moreover, multivariate analysis indicated that a smaller LVESVi at baseline was linked to 
greater magnitude of response to CRT which also suggests earlier intervention with CRT than 
indicated in present guidelines15,16,17. The magnitude of reverse remodeling in the higher LVEF 
group was less than observed in patients with severe heart failure and with worse LV function in 
the post hoc analysis of PROSPECT24. One contributing factor for this observation may be that 
patients in this group more often had underlying ischemic heart disease and shorter QRS duration 
which is known to be linked to less extensive reverse remodeling6,14,28,29. In the MIRACLE trial, 
the extent of reverse remodeling was half the magnitude in patients with ischemic etiology as in 
those with dilated cardiomyopathy28. Similar findings were made in the CARE-HF trial despite 
similar clinical benefit29. We have previously reported that ischemic heart failure patients in 
REVERSE had three times less reverse remodeling than patients with dilated cardiomyopathy30 
and that the magnitude of the QRS duration is an independent predictor of the extent of reverse 
remodeling14. The effect of QRS duration and etiology of heart failure on reverse remodeling has 
also been noted in studies of advanced HF31.  Thus, the greater proportion of patients with 
ischemic etiology and shorter mean QRS duration in the LVEF > 30% group may partly explain 
the smaller reverse remodeling. 
Nonetheless, CRT in LVEF > 30% was associated with significant clinical improvement as 
assessed by the time to mortality or hospitalizations for heart failure as in the LVEF < 30% 
group over a follow up period of 12-24 months. In fact, the relative risk reduction was 74% in 
the LVEF > 30% group compared to 42% in the LVEF < 30% group suggesting a greater 
benefit. CRT was independently associated with outcome independent of LVEF. Age or baseline 
ischemic heart disease and diabetes were not independent predictors of clinical outcome.  
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Electrical dyssynchrony is critical for CRT induced improvements with the response increasing 
with longer intrinsic QRS duration and in particular left bundle branch morphology13-14. Our 
patients all had wide QRS (155.7 ± 22.2 ms in the LVEF < 30% and 147±20.4 ms in the LVEF > 
30% group) and LBBB was present in about 60% of patients within each subgroup. These study 
results indicate that the benefits of CRT may be present for patients with QRS prolongation and 
mild HF with less severe left ventricular dysfunction than previously studied.  
Presence of electrical dyssynchrony in HF patients with reduced and preserved LVEF 
Approximately one third of HF patients have conduction disturbances evidenced by QRS 
duration > 120 ms32,33,34.  Although electrical dyssynchrony is more common in HF patients with 
reduced LVEF it is prevalent over a wide range of ejection fractions33 and linked to worse 
prognosis33,34. In a recent report from the Swedish heart failure registry33 39% of patients with 
LVEF< 40% , 25% with  LVEF 40-49% and 18% of patients with LVEF > 50% had QRS 
duration > 120 ms that was associated with risk for mortality regardless of ejection fraction. 
Similar observations were made in the CHARM studies also including mild heart failure 
patients35. These observations indicate that electrical dyssynchrony is present in HF patients with 
mild to moderate reduction in ventricular function and potentially might be influenced by CRT. 
The findings in the present analysis of HF patients with LVEF 31-40% are encouraging.  
 
Limitations: 
The study should be interpreted in light of certain methodological limitations.  This was a 
posthoc subgroup analysis that was not powered during study design and randomization was not 
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stratified based on EF.  There were also some important clinical differences between subgroups, 
although multivariate analysis indicated that EF was not an independent predictor of response.   
 
Conclusions:  
In this analysis of REVERSE study patients with LVEF > 30%, CRT produced improvements in 
time to death or heart failure related hospitalizations and were associated with significant 
reduction in left ventricular end-systolic volume index and left ventricular mass consistent with 
reverse remodeling.  These findings warrant further prospective validation. 
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Legends 
 
Figure 1. Distribution of center lab (top) and core lab (bottom) baseline left ventricular ejection 
fraction results in all patients.  
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Figure 2. Left ventricular reverse remodeling of LVESVi and LVEF with baseline LVEF > 30% 
(upper panel) or < 30% (lower panel) in relation to CRT ON and OFF assignment.  Error bars 
reflect 95% confidence intervals about the mean values. 
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Figure 3. Clinical composite response distribution in patients with baseline LVEF < 30% or > 
30% in relation to CRT ON and OFF assignment. 
 
Figure 4. Time to death or hospitalization for heart failure in patients with baseline LVEF < 30% 
or > 30% in relation to CRT ON and OFF assignment. 
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Table 1. Baseline clinical characteristics divided by LVEF < 30% and > 30%. 
 LVEF < 30% 
(n=431) 
LVEF > 30% 
(n=177) 
p-value1 
Clinical Characteristics    
Age, yrs 61.8 ± 11.3 64.2 ± 10.0 0.01 
Gender, male n (%) 336 (78) 142 (80) 0.59 
Ischemic, n (%) 222 (52) 110 (62) 0.02 
Hypertension, n(%) 216 (50) 98 (55) 0.25 
Diabetic, n (%) 93 (22) 43 (24) 0.46 
ACE inhibitors or ARBs, n (%) 416 (97) 172 (97) 0.81 
Beta-blockers, n (%) 405 (94) 173 (98) 0.06 
Intrinsic QRS width (ms) 155.7 ± 22.2 147.3 ± 20.4 < 0.0001 
QRS morphology 
  LBBB2, n (%) 
 
266 (62) 
 
102 (58) 
 
0.31 
  IVCD2, n (%) 127 (30) 54 (31) 
  RBBB2, n (%) 35 (8) 21 (12) 
Glomerular filtration rate( ml/min) 87.6 ± 34.1 82.0 ± 30.3 0.048 
Supine systolic BP, mm Hg 122.9 ± 18.1 129.1 ± 19.8 0.0003 
Supine diastolic BP, mm Hg 71.7 ± 10.9 73.2 ± 11.8 0.16 
CRT-ICD implanted, n (%) 361 (84) 145 (82) 0.63 
1 p-values were calculated using a t-test (assuming unequal variances) for continuous variables and Fisher’s exact test for categorical variables  
2 Sample sizes for QRS morphology are n=428 (LVEF < 30%) and n=177 (LVEF > 30%) 
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Table 2. Baseline functional characteristics and echocardiographic data divided by LVEF < 
30% and > 30%. 
 LVEF < 30% 
(n=431) 
LVEF > 30% 
(n=177) 
p-value1 
Functional Characteristics    
NYHA class II, n (%) 369 (86) 133 (75) 0.003 
LVEF(center), % 25.0 ± 6.8 30.7 ± 5.9 < 0.0001 
LVEF (core)2, % 23.6 ± 4.1 35.1 ± 3.9 < 0.0001 
LVEDD3, cm 7.1 ± 0.9 6.5 ± 0.9 < 0.0001 
LVESD3, cm 6.0 ± 1.0 5.2 ± 1.0 < 0.0001 
LV mass4, g 276.7 ± 75.9 253.6 ± 75.9 0.01 
LVESVi2, ml/m2 110.6 ± 37.6 74.5 ± 23.0 < 0.0001 
LVEDVi2, ml/m2 143.8 ± 43.7 114.3 ± 33.0 < 0.0001 
MLHFQ5, (0-105) 28.6 ± 20.8 25.0 ± 20.0 0.06 
KCCQ6, (0-100) 71.8 ± 20.2 75.3 ± 19.3 0.06 
6-min hall walk7, m 390.8 ± 128.2 409.5 ± 124.3 0.10 
1 p-values were calculated using a t-test (assuming unequal variances) for continuous variables and Fisher’s exact test for categorical variables  
2 Sample sizes for core lab LVEF, LVEDVi and LVESVi are n=399 (LVEF < 30%) and n=166 (LVEF > 30%) 
3 Sample sizes for LVEDD and LVESD are n=298 (LVEF < 30%) and n=114 (LVEF > 30%) 
4 Sample sizes for LV mass are n=281 (LVEF < 30%) and n=94 (LVEF > 30%) 
5 Sample sizes for MLWHF are n=420 (LVEF < 30%) and n=164 (LVEF > 30%) 
6 Sample sizes for KCCQ are n=374 (LVEF < 30%) and n=146 (LVEF > 30%) 
7 Sample sizes for 6-min hall walk are n=425 (LVEF < 30%) and n=176 (LVEF > 30%) 
 
Table 3. Changes in functional and echocardiographic variables from the baseline visit to the 12 month follow-up 
 divided by LVEF < 30% and > 30% at baseline. 
 LVEF < 30%  LVEF > 30%  Full study  
 
 
CRT OFF 
(n=141) 
CRT ON   
(n=290) 
p-value CRT OFF 
(n=50) 
CRT ON   
(n=127) 
p-value CRT OFF 
(n=191) 
CRT ON   
(n=419) 
p-value1 
CCR 
   % improved 
 
43 
 
57  
0.02 
 
30 
 
48  
0.06 
 
40 
 
54 
 
   % unchanged 34 27 54 36 39 30 0.003 
   % worsened 23 16 16 16 21 16  
NYHA class2 
   % improved 
 
22 
 
33.5  
0.055 
 
20 
 
28  
0.31 
 
22 
 
32 
 
   % unchanged 64 56.5 72 59 66 57 0.04 
   % worsened 14 10 8 13 12 11  
LVEF (core)3, % 2.5 ± 5.4 6.6 ± 9.2 < 0.0001 -3.8 ± 7.4 -0.1 ± 7.5 0.007 0.8 ± 6.6 4.6 ± 9.3 < 0.0001 
LVEDD4, cm 0.0 ± 0.6 -0.3 ± 0.8 0.002 -0.1 ± 0.7 -0.2 ± 0.7 0.63 -0.1 ± 0.6 -0.3 ± 0.8 0.005 
LVEDVi3, (ml/m2) -0.5 ± 29.6 -22.9 ± 33.8 < 0.0001 -4.3 ± 22.9 -11.2 ± 27.0  0.12 -1.5 ± 27.9 -19.3 ± 32.2 < 0.0001 
LVESVi3, (ml/m2) -2.9 ± 25.2 -23.5 ± 30.4 < 0.0001 2.1 ± 17.6 -6.7 ± 21.1 0.01 -1.6 ± 23.4 -18.3 ± 28.9 < 0.0001 
LV mass5, g -10.9 ± 49.9 -14.3 ± 53.4 0.65 5.0 ± 42.4 -20.6 ± 50.5 0.04 -7.6 ± 48.6 -16.0 ± 52.6 0.19 
MLHFQ6, (0-105) -7.4 ± 16.7 -9.0 ± 17.6 0.35 -4.7 ± 13.3 -6.7 ± 15.8 0.43 -6.7 ± 15.9 -8.4 ± 17.1 0.25 
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KCCQ7, (0-100) 9.6 ± 17.1 9.2 ± 18.4 0.84 5.6 ± 12.6 7.0 ± 15.7 0.56 8.5 ± 16.1 8.7 ± 17.8 0.92 
6-min hall walk8, (m) 27.7 ± 95.8 25.5 ± 93.6 0.83 13.5 ± 100.1 3.4 ± 109.0 0.56 23.8 ± 96.9 18.6 ± 98.8 0.55 
1 p-values were calculated using a t-test (unequal variance) for continuous variables and Fisher’s exact test for categorical variables  
2 Sample sizes for NYHA at 12 month follow-up are  n=416 (LVEF < 30%) and n=175 (LVEF > 30%) 
3 Sample sizes for core lab LVEF, LVEDVi and LVESVi are n=360 (LVEF < 30%) and n=149 (LVEF > 30%) 
4 Sample size for LVEDD is n=212 (LVEF < 30%) and n=79 (LVEF > 30%) 
5 Sample size for LV mass is n=202 (LVEF < 30%) and n=65 (LVEF > 30%) 
6 Sample size for MLWHF is n=404 (LVEF < 30%) and n=161 (LVEF > 30%) 
7 Sample size for KCCQ is n=362 (LVEF < 30%) and n=143 (LVEF > 30%) 
8 Sample size for 6-min hall walk is n=401 (LVEF < 30%) and n=171 (LVEF > 30%) 
Table 4.  ANCOVA models for echocardiographic parameters to adjust for regression to 
the mean 
 LVEF < 30% LVEF > 30% 
 CRT ON -CRT OFF p-value CRT ON - CRT OFF p-value 
LVEF (core)3, % 4.4 ± 0.9 < 0.0001 3.7 ± 1.3 0.003 
LVEDD4, cm -0.3 ± 0.1 0.003 -0.1 ± 0.2 0.63 
LVEDVi3, (ml/m2) -22.7 ± 3.5 < 0.0001 -7.3 ± 4.3  0.09 
LVESVi3, (ml/m2) -20.9 ± 3.2 < 0.0001 -9.0 ± 3.5 0.01 
LV stroke volume index, (ml/m2) -1.4 ± 0.9 0.16 1.6 ± 1.7 0.33 
LV mass5, g -7.1 ± 7.1 0.32 -26.6 ± 12.0 0.03 
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Table 5.  Multivariable Analysis of the Hazard Rate for Time to Death or HF 
Hospitalization using the Cox Proportional Hazards Model  
Baseline Parameter Units / Level Hazard Ratio p-value 
Unadjusted (n=608)    
CRT Yes 0.57 0.048 
LVEF > 30% Yes 0.77 0.55 
Interaction of CRT 
and LVEF > 30% 
Yes/Yes 0.44 0.21 
Adjusted (n=565)    
CRT Yes 0.54 0.035 
LVEF > 30% Yes 0.76 0.57 
Interaction of CRT 
and LVEF > 30% 
Yes/Yes 0.46 0.27 
Age Per 10 years 1.21 0.18 
QRS duration Per 10 ms 0.82 0.003 
LVESVi Per 10 ml/m2 1.14 0.0002 
Ischemic Yes 1.55 0.16 
Supine systolic BP Per 1 mm Hg 0.99 0.35 
Supine diastolic BP Per 1 mm Hg 1.02 0.38 
 
